These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder. Liguori C; Placidi F; Stefani A; Mercuri NB; Marciani MG; Stanzione P; Pierantozzi M Parkinsonism Relat Disord; 2015 Dec; 21(12):1476-8. PubMed ID: 26578038 [No Abstract] [Full Text] [Related]
3. The use of transdermal rotigotine in a patient with advanced Parkinson's disease and dysphagia. Christie J Palliat Med; 2007 Mar; 21(2):163-4. PubMed ID: 17443935 [No Abstract] [Full Text] [Related]
4. Safety and efficacy of rotigotine in individuals with Parkinson's disease aged 75 and older. Fasano A; Guidubaldi A; De Nigris F; Bentivoglio AR J Am Geriatr Soc; 2011 Dec; 59(12):2386-7. PubMed ID: 22188090 [No Abstract] [Full Text] [Related]
7. Synthesis and SAR study of a novel series of dopamine receptor agonists. Risgaard R; Jensen M; Jørgensen M; Bang-Andersen B; Christoffersen CT; Jensen KG; Kristensen JL; Püschl A Bioorg Med Chem; 2014 Jan; 22(1):381-92. PubMed ID: 24296012 [TBL] [Abstract][Full Text] [Related]
8. Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease. Chatsis V Issues Emerg Health Technol; 2008 Feb; (112):1-6. PubMed ID: 18354859 [No Abstract] [Full Text] [Related]
9. Transdermal rotigotine (Neupro) for Parkinson's disease. Med Lett Drugs Ther; 2007 Aug; 49(1268):69-70. PubMed ID: 17712291 [No Abstract] [Full Text] [Related]
10. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease. Naidu Y; Chaudhuri KR Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409 [TBL] [Abstract][Full Text] [Related]
11. Transdermal rotigotine in the treatment of aromatic L-amino acid decarboxylase deficiency. Mastrangelo M; Caputi C; Galosi S; Giannini MT; Leuzzi V Mov Disord; 2013 Apr; 28(4):556-7. PubMed ID: 23390030 [No Abstract] [Full Text] [Related]
12. The concept of continuous dopaminergic stimulation: what we should consider when starting Parkinson's disease treatment. Stocchi F Neurodegener Dis; 2010; 7(1-3):213-5. PubMed ID: 20224289 [TBL] [Abstract][Full Text] [Related]
13. Rotigotine: a viewpoint by Peter LeWitt. LeWitt P CNS Drugs; 2005; 19(11):983-4. PubMed ID: 16268668 [No Abstract] [Full Text] [Related]
14. Rotigotine: a viewpoint by Tomislav Babic. Babic T CNS Drugs; 2005; 19(11):983. PubMed ID: 16268669 [No Abstract] [Full Text] [Related]
15. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome. Splinter MY Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296 [TBL] [Abstract][Full Text] [Related]
16. [Rotigotine. One patch, two targets!]. Sabourin G Perspect Infirm; 2013; 10(4):60. PubMed ID: 24046901 [No Abstract] [Full Text] [Related]
17. [Rotigotine in the treatment of Parkinson's disease. A study on a sample of 150 patients]. Ruiz-Huete C; Bermejo PE; Terrón C; Anciones B Rev Neurol; 2008 Mar 1-15; 46(5):257-60. PubMed ID: 18351563 [TBL] [Abstract][Full Text] [Related]
18. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Parkinson Study Group Arch Neurol; 2003 Dec; 60(12):1721-8. PubMed ID: 14676046 [TBL] [Abstract][Full Text] [Related]
19. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease. Ruggieri S; Fabbrini G; Bramante L; DePandis F; Stocchi F; Barbanti P; Vacca L; Manfredi M Adv Neurol; 1996; 69():595-8. PubMed ID: 8615185 [No Abstract] [Full Text] [Related]